AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently Amended) A percutaneously absorbable preparation comprising sodium dichlorofenac a salt-form acidic drug and ammonium chloride an addition salt compound of a basic substance, wherein the ammonium chloride addition salt compound of the basic substance is blended at the range of from 0.5 to 10 fold mole based on the sodium dichlorofenac salt-form acidic drug.
 - (Cancelled).
 - 3. (Cancelled)
- 4. (Previously presented) The percutaneously absorbable preparation according to claim 1, wherein the percutaneously absorbable preparation is a nonaqueous preparation.
- 5. (Currently Amended) The percutaneously absorbable preparation according to claim 1, wherein the percutaneously absorbable preparation is a matrix-type patch or an ointment.
 - 6. (Cancelled)
- 7. (Currently amended) The percutaneously absorbable preparation according to claim [[6]] 1, wherein the salt-form acidic drug is an anti-inflammatory drug

Y. Takada, et al. U.S.S.N. 10/030,825 Page 3

and the <u>ammonium chloride</u> addition salt compound of the basic substance is combined at the range of from 0.5 to 7 fold mole based on the <u>sodium dichlorofenac</u> anti-inflammatory drug having salt-form.

- 8. (Currently Amended) The percutaneously absorbable preparation according to claim 7 any one of claims 1, 4-5 or 7, which is a matrix-type percutaneously absorbable preparation, wherein the sodium dichlorofenac anti-inflammatory drug having salt-form and the ammonium chloride addition salt-compound of the basic subwstance are contained in an adhesive basis layer.
- 9. (Currently amended) The matrix-type percutaneously absorbable preparation according to claim 8, wherein the adhesive basis layer is composed of one or more than two of <u>sstylene_s</u>
- 10. (Currently Amended) A percutaneous absorption accelerating composition of sodium dichlorofenac f the salt form acidic drug, which contains ammonium chloride the addition salt compound of the basic substance, wherein the ammonium chloride addition salt compound of the basic substance is blended at the range of from 0.5 to 10 fold mole based on the sodium dichlorofenac salt-form acidic drug.

11. - 12. (Cancelled)